First test: how does a damaged liver handle a new drug?
NCT ID NCT05718258
Summary
This early-stage study aimed to understand how liver problems affect how the body processes a single dose of an experimental drug called venglustat. It involved 26 adults, some with varying levels of liver impairment and others with normal liver function. The main goal was to measure drug levels in the blood and check for safety to see if dosing needs adjustment for people with liver disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC FUNCTION ABNORMAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
American Research Corporation Site Number : 8400005
San Antonio, Texas, 78215, United States
-
Clinical Pharmacology of Miami Site Number : 8400002
Miami, Florida, 33014, United States
-
Inland Empire Liver Foundation Site Number : 8400004
Rialto, California, 92377, United States
-
Investigational Site Number : 2760001
Kiel, 24105, Germany
-
Nucleus Network Site Number : 8400001
Saint Paul, Minnesota, 55114, United States
-
Volunteer Research Group-NOCCR Site Number : 8400003
Knoxville, Tennessee, 37920, United States
Conditions
Explore the condition pages connected to this study.